CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 875 enrolled
Drug / intervention
13vPnC +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03835975
NCT03835975Phase 3Completed
CompareCT.gov

A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION

Pfizer·interventional·Posted Feb 11, 2019·Updated Feb 21, 2021

In Brief

A Phase 3 clinical trial evaluating 13vPnC, PPSV23, and 1 other intervention for Pneumococcal Disease. Completed, enrolled 875 participants across 42 sites in 2 countries.

Detailed Summary

This Phase 3 will describe the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine formulation in adults 65 years of age or older with prior pneumococcal vaccination

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Disease
CountriesSweden, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedFeb 11, 2019
Enrollment StartFeb 12, 2019
Primary CompletionFeb 12, 2020
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 7.4 years ago

Interventions

13vPnCbiological

Pneumococcal conjugate vaccine

PPSV23biological

Pneumococcal polysaccharide vaccine

20vPnCbiological

Pneumococcal conjugate vaccine